Sundance Biosciences Shares Positive SUN-627 Trial Data
The oral TYK2 inhibitor showed strong inhibition and central nervous system penetration in a Phase 1 clinical study.
Live Poll
Do you trust that pharmaceutical companies are adequately prioritizing treatments for progressive chronic diseases?